Cover Image

Dyshidrotic bullous pemphigoid developing after Moderna mRNA-1273 vaccination

Saved in:

Bibliographic Details
Main Authors:	Tyng-Shiuan Hsieh (Author), Jau-Shiuh Chen (Author), Tsen-Fang Tsai (Author)
Format:	Book
Published:	Wolters Kluwer Medknow Publications, 2023-01-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Bullous drug eruption after second dose of mRNA-1273 (Moderna) COVID-19 vaccine: Case report
by: Joyce Kong, et al.
Published: (2021)

Herpes zoster reactivation after mRNA-1273 (Moderna) SARS-CoV-2 vaccination
by: Leelakrishna Channa, BS, et al.
Published: (2021)

Safety outcomes associated with the moderna COVID-19 vaccine (mRNA-1273): a literature review
by: Angel Shabu, et al.
Published: (2023)

Adult‐onset Still's disease following mRNA‐1273 Moderna COVID‐19 vaccination: A case report
by: Masahiro Iwata, et al.
Published: (2023)

Bullous pemphigoid in a patient with psoriasis after mRNA COVID‐19 vaccination
by: Arbie Sofia P. Merilleno, et al.
Published: (2023)

Acute Myocarditis Following Vaccination With the First Dose of the mRNA-1273 Vaccine
by: Abdulbaril Olagunju MD, et al.
Published: (2022)

Hypersensitivity reactions following the Moderna messenger RNA-1273 vaccine
by: Alex Drohan, MD, et al.
Published: (2021)

A case of new-onset palmoplantar pustulosis following mRNA COVID-19 vaccination
by: Yun-Shiuan Olivia Hsu, et al.
Published: (2023)

New-onset chilblains in close temporal association to mRNA-1273 vaccination
by: Connie Kha, MD, et al.
Published: (2021)

Analysis of the adverse events following the mRNA-1273 COVID-19 vaccine
by: Angel Shabu, et al.
Published: (2023)

Acute Generalized Exanthematous Pustulosis in Close Temporal Association with mRNA-1273 Vaccine
by: Fouad Mitri, et al.
Published: (2021)

Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
by: Bradley K. Ackerson, et al.
Published: (2024)

Atrial Fibrillation After mRNA-1273 SARS-CoV-2 Vaccination: Case Report with Literature Review
by: Chen CY, et al.
Published: (2023)

Erythema multiforme reactions after Pfizer/BioNTech (BNT162b2) and Moderna (mRNA-1273) COVID-19 vaccination: A case series
by: Elif Karatas, MD, et al.
Published: (2023)

A Case of Hypophysitis Following Immunization With the mRNA-1273 SARS-CoV-2 Vaccine
by: Natia Murvelashvili MD, et al.
Published: (2021)

Combination Therapy for Psoriasis with Methotrexate and Other Oral Disease-Modifying Antirheumatic Drugs: A Systematic Review
by: Tyng-Shiuan Hsieh, et al.
Published: (2023)

Moderna (mRNA Vaccine) for COVID-19: A Leap in Vaccine World
by: Anita Rani Bhatia, et al.
Published: (2022)

Two cases with generalised bullous cutaneous reactions after COVID‐19 mRNA vaccine Moderna (Spikevax®) and Pfizer-BioNTech (Comirnaty®)
by: Charlotte E. Rinnooy Kan, et al.
Published: (2024)

Immunoglobulin M bullous pemphigoid: An enigma
by: Rosalie Baardman, MD, et al.
Published: (2020)

A review of the immunogenicity and safety of booster doses of omicron variant-containing mRNA-1273 COVID-19 vaccines in adults and children
by: Frances Priddy, et al.
Published: (2024)

Real-world effectiveness of the mRNA-1273 vaccine against COVID-19: Interim results from a prospective observational cohort study
by: Katia J. Bruxvoort, et al.
Published: (2022)

Multiple Keratoacanthomas Following Moderna Messenger RNA-1273 COVID-19 Vaccination Resolved With 5-Fluorouracil Treatment: Case Report
by: Fahad Ahmed, et al.
Published: (2022)

Pseudo-Pemphigoid Gestationis Eruption Following SARS-CoV-2 Vaccination with mRNA Vaccine
by: Caroline de Lorenzi, et al.
Published: (2022)

Lymphocytic thrombophilic arteritis following mRNA-1273 severe acute respiratory syndrome coronavirus 2 vaccination: A case report and review of the literature
by: Hsin-Yu Huang, et al.
Published: (2023)

Maintenance of Potent Cellular and Humoral Immune Responses in Long-Term Hemodialysis Patients after 1273-mRNA SARS-CoV-2 Vaccination
by: Maria Gonzalez-Perez, et al.
Published: (2023)

mRNA as a Therapeutics: Understanding mRNA Vaccines
by: Ferdi Oğuz, et al.
Published: (2022)

Bullous pemphigoid
by: Denise Miyamoto, et al.

Development of mRNA rabies vaccines
by: Zixin Fang, et al.
Published: (2024)

Anti-spike antibodies and neutralising antibody activity in people living with HIV vaccinated with COVID-19 mRNA-1273 vaccine: a prospective single-centre cohort study
by: Andrea Lombardi, et al.
Published: (2022)

SARS-CoV-2 IgG Spike antibody levels and avidity in natural infection or following vaccination with mRNA-1273 or BNT162b2 vaccines
by: Thomas E. Hickey, et al.
Published: (2023)

Cutaneous dermatophytosis mimicking bullous pemphigoid or typical bullous pemphigoid and tinea incognito?
by: Tirado-Sánchez Andrés, et al.
Published: (2019)

Erythrodermic bullous pemphigoid
by: Mai Endo, et al.
Published: (2021)

Efficacy and tolerance of upadacitinib in the treatment of dyshidrotic eczema
by: Benjamin Matthew Kiszla, BS, et al.
Published: (2023)

Serious adverse reaction associated with the COVID-19 vaccines of BNT162b2, Ad26.COV2.S, and mRNA-1273: Gaining insight through the VAERS
by: Ming-Ming Yan, et al.
Published: (2022)

No immunological interference or concerns about safety when seasonal quadrivalent influenza vaccine is co-administered with a COVID-19 mRNA-1273 booster vaccine in adults: A randomized trial
by: Abdi Naficy, et al.
Published: (2024)

Gliptin-associated Bullous Pemphigoid and the Expression of Dipeptidyl Peptidase-4/CD26 in Bullous Pemphigoid
by: Outi Lindgren, et al.
Published: (2019)

Semaglutide-associated bullous pemphigoid
by: Clayton P. Burruss, BS, et al.
Published: (2021)

Coexistence of psoriasis with bullous pemphigoid
by: Raghavendra Rao, et al.
Published: (2012)

Localized flexural bullous pemphigoid
by: Mehta Vandana, et al.
Published: (2008)

Bullous Pemphigoid Mimicking Cellulitis
by: Ilya Ivyanskiy, et al.
Published: (2021)